Seal Rock Therapeutics Inc. has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. The program supports the development of new therapies targeting LRRK2 for the treatment of Parkinson’s disease patients and fosters international collaboration across more than 30 academic and clinical centers and more than a dozen companies.

Lysoway Therapeutics Inc. announced that it has received a research grant of $2.93 million from The Michael J. Fox Foundation for Parkinson's Research. The funding will support the preclinical development of Lysoway’s highly brain-penetrant small molecule mucolipin TRP Cation channel 1 (MCOLN1/TRMPL1) agonist.

Congruence Therapeutics Inc. has received a research grant of $5 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its GCase-targeting small molecules for GBA1 Parkinson’s disease. Mutations of the GBA1 gene, encoding the enzyme GCase, represent the single largest genetic risk factor for Parkinson’s disease.

1st Biotherapeutics Inc. has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program.

Lario Therapeutics Ltd. has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Alchemab Therapeutics Ltd. has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program.

Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease.